Identification of Potential Surrogate Endpoints in Randomized Clinical Trials of Aggressive Non-Hodgkin Lymphoma: Correlation of Complete Response, Time-to-Event and Overall Survival Data

被引：0
|
作者：
Lee, Linda M. [1 ]
Wang, Lisa [1 ]
Crump, Michael [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1424 / 1424
页数：1
相关论文
共 18 条
  • [1] Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
    Lee, L.
    Wang, L.
    Crump, M.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (06) : 1392 - 1403
  • [2] Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials
    Fiteni, Frederic
    Paillard, Marie-Justine
    Westeel, Virginie
    Bonnetain, Franck
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 167 - 173
  • [3] Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma
    Last, KW
    Cornelius, V
    Delves, T
    Sieniawska, C
    Fitzgibbon, J
    Norton, A
    Amess, J
    Wilson, A
    Rohatiner, AZS
    Lister, TA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2335 - 2341
  • [4] Potential Surrogate Endpoints for Progression-Free Survival (PFS) and Overall Survival (OS) in Non-Hodgkin Lymphoma: A Literature-Based Meta-analysis of Phase II and Phase III Studies
    Zhu, Rui
    Lu, Dan
    Chu, Wayne
    Chai, Akiko
    Green, Michelle
    Zhang, Nancy
    Jin, Jin Yan
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S78 - S78
  • [5] Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials
    Broeckelmann, Paul J.
    Mueller, Horst
    Gillessen, Sarah
    Jacob, Anne Sophie
    Momotow, Jesko
    Damaschin, Carla
    Ferdinandus, Justin
    Yang, Xiaoqin
    Fuchs, Michael
    Kobe, Carsten
    Eich, Hans Theodor
    Engert, Andreas
    Borchmann, Peter
    von Tresckow, Bastian
    [J]. BLOOD, 2023, 142
  • [6] A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials
    Horiguchi, Miki
    Cronin, Angel M.
    Takeuchi, Masahiro
    Uno, Hajime
    [J]. STATISTICS IN MEDICINE, 2018, 37 (15) : 2307 - 2320
  • [7] Correlation between progression-free and overall survival in patients with classical Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized GHSG trials
    Broeckelmann, P.
    Mueller, H.
    Gillessen, S.
    Jacob, A. S.
    Momotow, J.
    Damaschin, C.
    Ferdinandus, J.
    Yang, X.
    Fuchs, M.
    Kobe, C.
    Eich, H. T.
    Engert, A.
    Borchmann, P.
    von Tresckow, B.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 110 - 110
  • [8] Association of lymphocyte to monocyte ratio with clinical response and survival in patients with relapsed, aggressive non-Hodgkin lymphoma treated with axicabtagene ciloleucel CAR-T.
    Al Saleh, Abdullah S.
    Gandhi, Sangeetha
    Tuan Truong
    Khurana, Arushi
    Brandes, Eva
    Estby, Breanna
    Lange, Gina
    Ansell, Stephen M.
    Bennani, N. Nora
    Johnston, Patrick B.
    Paludo, Jonas
    Villasboas, Jose Caetano
    Porrata, Luis F.
    Lin, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials
    Mangal, Naveen
    Salem, Ahmed Hamed
    Li, Mengyao
    Menon, Rajeev
    Freise, Kevin J.
    [J]. HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 37 - 43
  • [10] Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial
    Ezzat, AA
    Ibrahim, EM
    Stuart, RK
    Ajarim, D
    Bazarbashi, S
    El-Foudeh, MO
    Rahal, M
    Al-Sayed, A
    Berry, J
    [J]. MEDICAL ONCOLOGY, 2000, 17 (01) : 39 - 46
12